case_images: PMC10601776_01
case_images: PET CT images taken at different time points. a Lung nodule after 10 months of SBRT and prior to initiation of personalized treatment regimen in August 2018; (b) lung nodule with cavitation and surrounding fibrosis likely to be RT induced in September 2020; (c) lung nodule with cavitation and surrounding fibrosis in May 2022; and (d) lung nodule with cavitation and surrounding fibrosis in June 2023. SBRT, stereotactic body radiation therapy.
case_images: cro-2023-0016-0001-533760_F01.jpg
case_images: PMC10601776_01_cro-2023-0016-0001-533760_F01.jpg
case_images: F1
case_images: The PET-CT showed a progression of the disease (Fig. 1a). April 2023, but the patient continued to take pembrolizumab and bevacizumab. After 75 cycles up until June 2023, the patient remained in residual metabolic disease status with no new lesions (Fig. 1b-d).
case_images: A timeline that summarizes the main events of the case.
case_images: cro-2023-0016-0001-533760_F02.jpg
case_images: PMC10601776_01_cro-2023-0016-0001-533760_F02.jpg
case_images: F2
case_images: Figure 2 depicts a timeline that summarizes the main events of the case.